Another anti-PD-1 antibody, pembrolizumab, has been studied in a multicenter, randomized Phase II KEYNOTE-224 study (NCT02702414) in sorafenib-refractory advanced HCC patients (28). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.